Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Non-Current Assets (2021 - 2025)

Valion Bio has reported Non-Current Assets over the past 5 years, most recently at $18.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 10972.02% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $26.3 million, up 2586.3%, while the annual FY2025 figure was $18.6 million, 10972.02% up from the prior year.
  • Non-Current Assets for Q4 2025 was $18.6 million at Valion Bio, up from $2.5 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $18.6 million in Q4 2025 and troughed at $120000.0 in Q2 2024.
  • A 5-year average of $1.9 million and a median of $614000.0 in 2022 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: tumbled 79.87% in 2024 and later skyrocketed 10972.02% in 2025.
  • Year by year, Non-Current Assets stood at $747000.0 in 2021, then fell by 23.83% to $569000.0 in 2022, then dropped by 11.25% to $505000.0 in 2023, then crashed by 66.73% to $168000.0 in 2024, then skyrocketed by 10972.02% to $18.6 million in 2025.
  • Business Quant data shows Non-Current Assets for TIVC at $18.6 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.